Abstract
In an era of cost-consciousness in the delivery of medical care, the economics of healthcare delivery for HIV-infected persons has been an area of active interest. Interested parties include the payors of HIV care, particularly public insurers, who are paying for an increasing amount of the overall cost of HIV care in the US; providers of care, many of whom are finding it increasingly difficult to provide HIV care in a capitated market; and those persons who are HIV-infected and increasingly caught in the economic turmoil of the HIV healthcare marketplace. This paper will review the literature published over the past year regarding the economics of healthcare for HIV in the US.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Scitovsky AA, Cline M, Lee PR: Medical care costs of patients with AIDS in San Francisco. JAMA 1986, 256:3103–3109.
Hellinger FJ: The lifetime cost of treating a person with HIV. JAMA 1993, 270:474–478.
Moore RD, Chaisson RE: Costs to Medicaid of advancing immunosuppression in an urban HIV infected patient population in Maryland. J Acquir Immun Defic Syndr Hum Retrovirol 1997, 14:223–231.
Hurley SF, Kalder JM, Gardiner S, et al.: Lifetime cost of HIVrelated health care. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 12:371–378.
Petrou S, Dooley M, Whitaker L, et al.: The economic costs of caring for people with HIV infection in England and Wales. Pharmacoeconomics 1996, 9:332–340.
Torres RA, Barr M: Impact of combination therapy for HIV infection on inpatient census. N Engl J Med 1997, 336:1531–1532.
Kaiser P, Kvanli MB, Turner D, et al.: Protease inhibitor based therapy is associated with decreased HIV related health care costs. J Acquir Immune Defic Syndr Hum Retrovirol 1999, 20:28–33.
Gebo KA, Chaisson RE, Folkemer JG, et al.: Costs of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999, 13:963–969. This study of patients in a large urban HIV primary care practice demonstrates that the costs of HIV care decline in patients receiving highly active antiretroviral therapy. This decline occurs particularly in hospital inpatient costs for patients with more advanced levels of immunosuppression.
Mouton Y, Alfandair S, Valette M, et al.: Impact of protease inhibitors on AIDS-defining events and hospitalization in 10 French AIDS centers. AIDS 1997, 11:101–105.
Stansell JD, Daly R, Hamel E, et al.: Decreased healthcare utilization with increased use of protease inhibitors in HIV+ patients [abstract]. In Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 1999.
Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med 1998, 338:853–860.
Ledergerber B, Egger M, Erard V, et al.: AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy. JAMA 1999 282:2220–2226.
Moore RD, Chaisson RE: Natural history of HIV infection in the era of combination antiretroviral therapy. AIDS 1999, 13:1933–1942. This article focuses on two studies of the evolving natural history of HIV infection in the U.S. and Europe. Published in 1999, each shows a reduction in mortality in almost all of the individual AIDS-defining illnesses (except lymphoma, which has not shown an increase), through the end of 1998. Both studies also suggest that the beneficial effect of potent antiretroviral drug therapy is realized regardless of the patient;s gender, race, or HIV transmission risk group.
Moore RD, Bartlett JG: Combination antiretroviral therapy in HIV infection: an economic perspective. Pharmacoeconomics 1996, 10:109–113.
Cook J, Dasbach E, Coplan P, et al.: Modeling the long-term outcomes and costs of HIV antiretroviral therapy using HIV RNA levels: application to a clinical trial. AIDS Res Hum Retroviruses 1999, 15:499–508.
Risebrough N, Oh P, Rachlis A, et al.: Economic evaluation of triple ART with indinavir or abacovir and ZDV+3TC compared to dual therapy ZDV+3TC [abstract]. In Proceedings of the Conference on Retroviruses and Opportunistic Infection. Chicago, 1999.
Freedberg KA, Goldie SJ, Paltiel AD, Zhang EH, Cohen CJ, Seage GR, et al.: Combination antiretroviral therapy is both effective and cost-effectiveness [abstract]. In Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 1999.
Gulick R, Mellors J, Havlir D, et al.: Treatment with indinavir, zidovudine, and lamivudine: Three-year follow-up [abstract]. In Proceedings of the Conference on Retroviruses and Opportunistic Infection. Chicago, 1999.
Lucas GM, Chaisson RE, Moore RD: Highly active antiretroviral therapy in a large urban clinic: risk factors for virological failure and adverse drug reactions. Ann Intern Med 1999, 131:81–87. This clinical practice-based study demonstrates that there may be a lower success rate for HAART in clinical practice than in controlled clinical trials. These data are consistent with other so-called “real-life” experiences in inner city clinics and illustrate the challenge in treating patient populations that represent the current HIV epidemic in the U.S.
Witek J, Dean L, Evangelista L, Gold M: Is HAART enough? [abstract]. In Proceedings of the Conference on Retroviruses and Opportunistic Infection. San Francisco, 2000.
Chowdhry T, Valdez H, Assad R, et al.: The changing spectrum of HIV mortality: analysis of 249 deaths from 1995–1999 [abstract]. In Proceedings of the Conference on Retroviruses and Opportunistic Infection. San Francisco, 2000.
Shapiro MF, Morton SC, McCaffrey DF, et al.: Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA 1999, 281:2305–2315. This is a nationally-representative study of patients receiving HIV care in the United States from 1996 through January 1998. It demonstrates relatively high access to HIV care (an average of 80% of HIV-infected patients receiving antiretroviral therapy). It also suggests some disparities in access to therapy based on race, gender, and medical insurer.
Keruly JC, Moore RD: Comparison of health outcomes for persons funded by the Ryan White CARE Act and by other sources. In Proceedings of the Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, 1999.
Marx R, Chang SW, Park MS, Katz MH: Reducing financial barriers to HIV-related medical care: does the Ryan White CARE Act make a difference? AIDS Care 1998, 10:611–616.
O’Neill JF: Paying for HIV/AIDS care at the turn of the century. Am J Manag Care 1999, 5:1442.
Singer B, Gamliel S, Conviser R: Developing a managed care delivery system for people with HIV/AIDS. Am J Manag Care 1999, 5:1443.
Hogg RS, Weber AE, Craib KJ, et al.: One world, one hope: the cost of providing antiretroviral therapy to all nations. AIDS 1998, 12:2203–2209.
Forsythe S: The affordability of antiretroviral therapy in developing countries: what policymakers need to know [abstract]. In Proceedings of the International AIDS Conference.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Moore, R.D. Healthcare economics in HIV. Curr Infect Dis Rep 2, 371–375 (2000). https://doi.org/10.1007/s11908-000-0018-8
Issue Date:
DOI: https://doi.org/10.1007/s11908-000-0018-8